Yatin Suneja
Stock Analyst at Guggenheim
(2.27)
# 1,463
Out of 4,479 analysts
86
Total ratings
43.28%
Success rate
-3.88%
Average return
Main Sectors:
34 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Initiates: Buy | $155 | $39.27 | +294.70% | 1 | Jun 18, 2024 | |
| QTTB Q32 Bio | Initiates: Buy | $100 | $18.05 | +454.02% | 1 | Jun 17, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Neutral | n/a | $2.79 | - | 3 | May 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $164 → $170 | $137.49 | +23.65% | 2 | May 2, 2024 | |
| ABVX Abivax | Initiates: Buy | $50 | $13.50 | +270.37% | 1 | Apr 29, 2024 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $72 → $90 | $37.01 | +143.18% | 3 | Feb 27, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $110 → $125 | $78.93 | +58.37% | 7 | Feb 21, 2024 | |
| LBPH Longboard Pharmaceuticals | Maintains: Buy | $16 → $32 | $30.74 | +4.10% | 3 | Jan 2, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $17 → $16 | $10.56 | +51.52% | 2 | Nov 15, 2023 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $70 → $77 | $40.15 | +91.78% | 3 | Nov 15, 2023 | |
| TRML Tourmaline Bio | Initiates: Buy | $50 | $12.55 | +298.41% | 1 | Oct 31, 2023 | |
| NMRA Neumora Therapeutics | Initiates: Buy | $22 | $9.80 | +124.49% | 1 | Oct 10, 2023 | |
| SEEL Seelos Therapeutics | Downgrades: Neutral | n/a | $0.59 | - | 3 | Sep 22, 2023 | |
| IMVT Immunovant | Reiterates: Buy | $32 | $26.52 | +20.66% | 5 | Sep 22, 2023 | |
| CABA Cabaletta Bio | Reiterates: Buy | $34 | $7.39 | +360.08% | 2 | Aug 14, 2023 | |
| ARGX argenx SE | Maintains: Buy | $545 → $590 | $435.49 | +35.48% | 3 | Jul 28, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $935 → $900 | $1,044.66 | -13.85% | 3 | Jul 17, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Neutral | n/a | $1.12 | - | 3 | Jul 17, 2023 | |
| ZURA Zura Bio | Initiates: Buy | $20 | $3.43 | +483.09% | 1 | Jun 22, 2023 | |
| XENE Xenon Pharmaceuticals | Reiterates: Buy | $49 | $36.56 | +34.03% | 2 | Jun 15, 2023 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Buy | $52 → $55 | $8.01 | +586.64% | 2 | May 18, 2023 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $12 → $14 | $7.71 | +81.58% | 3 | May 17, 2023 | |
| ANAB AnaptysBio | Maintains: Buy | $44 → $45 | $23.94 | +87.97% | 5 | May 12, 2023 | |
| BIIB Biogen | Upgrades: Buy | $270 → $350 | $228.82 | +52.96% | 3 | May 1, 2023 | |
| IFRX InflaRx | Upgrades: Buy | $8 | $1.73 | +362.43% | 2 | Apr 5, 2023 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $22 | $15.84 | +38.89% | 5 | Jan 3, 2023 | |
| SAGE Sage Therapeutics | Downgrades: Neutral | n/a | $10.82 | - | 4 | Jan 3, 2023 | |
| SRZN Surrozen | Downgrades: Neutral | n/a | $10.22 | - | 2 | Nov 18, 2022 | |
| VIGL Vigil Neuroscience | Maintains: Buy | $22 → $19 | $4.01 | +374.41% | 1 | Nov 11, 2022 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $42 → $30 | $10.25 | +192.68% | 2 | Nov 11, 2022 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | n/a | $2.99 | - | 3 | Oct 14, 2022 | |
| BLCO Bausch + Lomb | Initiates: Buy | $24 | $14.66 | +63.71% | 1 | May 31, 2022 | |
| ELYM Eliem Therapeutics | Downgrades: Neutral | n/a | $6.81 | - | 2 | Apr 26, 2022 | |
| VRNA Verona Pharma | Initiates: Buy | n/a | $15.46 | - | 1 | May 22, 2017 |
Praxis Precision Medicines
Jun 18, 2024
Initiates: Buy
Price Target: $155
Current: $39.27
Upside: +294.70%
Q32 Bio
Jun 17, 2024
Initiates: Buy
Price Target: $100
Current: $18.05
Upside: +454.02%
RAPT Therapeutics
May 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.79
Upside: -
Neurocrine Biosciences
May 2, 2024
Maintains: Buy
Price Target: $164 → $170
Current: $137.49
Upside: +23.65%
Abivax
Apr 29, 2024
Initiates: Buy
Price Target: $50
Current: $13.50
Upside: +270.37%
Celldex Therapeutics
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $37.01
Upside: +143.18%
Axsome Therapeutics
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $78.93
Upside: +58.37%
Longboard Pharmaceuticals
Jan 2, 2024
Maintains: Buy
Price Target: $16 → $32
Current: $30.74
Upside: +4.10%
Roivant Sciences
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $10.56
Upside: +51.52%
MoonLake Immunotherapeutics
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $40.15
Upside: +91.78%
Tourmaline Bio
Oct 31, 2023
Initiates: Buy
Price Target: $50
Current: $12.55
Upside: +298.41%
Neumora Therapeutics
Oct 10, 2023
Initiates: Buy
Price Target: $22
Current: $9.80
Upside: +124.49%
Seelos Therapeutics
Sep 22, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.59
Upside: -
Immunovant
Sep 22, 2023
Reiterates: Buy
Price Target: $32
Current: $26.52
Upside: +20.66%
Cabaletta Bio
Aug 14, 2023
Reiterates: Buy
Price Target: $34
Current: $7.39
Upside: +360.08%
argenx SE
Jul 28, 2023
Maintains: Buy
Price Target: $545 → $590
Current: $435.49
Upside: +35.48%
Regeneron Pharmaceuticals
Jul 17, 2023
Maintains: Buy
Price Target: $935 → $900
Current: $1,044.66
Upside: -13.85%
BioXcel Therapeutics
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Zura Bio
Jun 22, 2023
Initiates: Buy
Price Target: $20
Current: $3.43
Upside: +483.09%
Xenon Pharmaceuticals
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $36.56
Upside: +34.03%
EyePoint Pharmaceuticals
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $8.01
Upside: +586.64%
Larimar Therapeutics
May 17, 2023
Maintains: Buy
Price Target: $12 → $14
Current: $7.71
Upside: +81.58%
AnaptysBio
May 12, 2023
Maintains: Buy
Price Target: $44 → $45
Current: $23.94
Upside: +87.97%
Biogen
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $228.82
Upside: +52.96%
InflaRx
Apr 5, 2023
Upgrades: Buy
Price Target: $8
Current: $1.73
Upside: +362.43%
ACADIA Pharmaceuticals
Jan 3, 2023
Upgrades: Buy
Price Target: $22
Current: $15.84
Upside: +38.89%
Sage Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $10.82
Upside: -
Surrozen
Nov 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $10.22
Upside: -
Vigil Neuroscience
Nov 11, 2022
Maintains: Buy
Price Target: $22 → $19
Current: $4.01
Upside: +374.41%
Phathom Pharmaceuticals
Nov 11, 2022
Maintains: Buy
Price Target: $42 → $30
Current: $10.25
Upside: +192.68%
Relmada Therapeutics
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.99
Upside: -
Bausch + Lomb
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $14.66
Upside: +63.71%
Eliem Therapeutics
Apr 26, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.81
Upside: -
Verona Pharma
May 22, 2017
Initiates: Buy
Price Target: n/a
Current: $15.46
Upside: -